3D Medicines, Inc. (1244) Stock Statistics & Valuation Metrics

3D Medicines, Inc. has a market cap or net worth of HK$1.63B. The enterprise value is HK$404.93M.

3D Medicines, Inc. has 258,177,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

3D Medicines, Inc.’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -13.11%.

The current PE Ratio of 3D Medicines, Inc. is ―. 3D Medicines, Inc.’s PEG ratio is 0.06.

In the last 12 months, 3D Medicines, Inc. had revenue of 445.65M and earned -182.66M in profits. Earnings per share was -0.75.

In the last 12 months, operating cash flow was -48.66M and capital expenditures 510.00K, giving a free cash flow of -55.38M billion.

3D Medicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

3D Medicines, Inc. upcoming earnings date is Mar 26, 2026, TBA (Not Confirmed).

3D Medicines, Inc. as a current ratio of 2.02, with Debt / Equity ratio of 22.76%

In the past 12 months, 3D Medicines, Inc. has paid 0.00 in taxes.

3D Medicines, Inc. EV to EBITDA ratio is -2.15, with an EV/FCF ratio of -1.96.

3D Medicines, Inc. has HK$447.10M in cash and marketable securities with HK$162.97M in debt, giving a net cash position of HK$284.13M billion.

Gross margin is 83.34%, with operating margin of -27.70%, and net profit margin of -40.99%.

The average price target for 3D Medicines, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―